Therapeutics News and Research

RSS

New study examines single 'transformer' proteins involved in cancer

A new study led by scientists at The Scripps Research Institute and St. Jude Children's Research Hospital shows how a protein involved in cancer twists and morphs into different structures.

22 Dec 2015

Scientists identify 52 genetic variations associated with age-related macular degeneration

In one of the latest examples of precision medicine, teams of geneticists from nine countries, involving more than 100 scientists, analyzed the genes of more than 33,000 individuals in the hope of finding genetic variations responsible for age-related macular degeneration (AMD), the leading cause of vision loss among people age 50 or older.

22 Dec 2015

Small airway-on-a-chip enables analysis of human COPD and asthma

A research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University leveraged its organ-on-a-chip technology to develop a model of the human small airway in which lung inflammatory diseases, such as chronic obstructive pulmonary disease (COPD), the third leading cause of mortality worldwide, and asthma can be studied outside the human body.

22 Dec 2015

Alexza reports interim results from AZ-002 Phase 2a study in epilepsy patients

Alexza Pharmaceuticals, Inc. today announced interim results of its Phase 2a study of AZ-002 (Staccato alprazolam) in epilepsy patients. AZ-002 produced a dose-related decrease in mean Standardized Photosensivity Range (SPR), the primary endpoint in the study.

21 Dec 2015

Nuvo Research announces topline results from WF10 Phase 2 trial for treatment of allergic rhinitis

Nuvo Research Inc., a life sciences company with growing revenues and a diverse portfolio of topical products, today announced the results of its investigational Phase 2 clinical trial of WF10 (Trial) for the treatment of allergic rhinitis.

21 Dec 2015

Halozyme Therapeutics, Lilly sign global collaboration and license agreement

Halozyme Therapeutics, Inc. today announced a global collaboration and license agreement with Eli Lilly and Company to develop and commercialize products combining proprietary Lilly compounds with Halozyme's ENHANZE platform.

21 Dec 2015

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

Mirati Therapeutics, Inc. today announced that the Phase 2 clinical trial of glesatinib (MGCD265) has commenced. The Company also announced that "glesatinib" is the proposed generic name for MGCD265.

21 Dec 2015

Regulus begins RG-125(AZD4076) Phase I study for treatment of NASH in patients with type 2 diabetes/pre-diabetes

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-125(AZD4076), by its collaboration partner AstraZeneca.

21 Dec 2015

Adaptimmune begins Phase I/II study of affinity enhanced T-cell therapy targeting MAGE-A10 in NSCLC patients

Adaptimmune Therapeutics plc, a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has initiated a Phase I/II study of its affinity enhanced T-cell therapy targeting the MAGE-A10 cancer antigen in patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC), the most prevalent type of lung cancer representing approximately 85 percent of lung cancers.

21 Dec 2015

Synthetic biomaterial aids in regeneration of skin cells to improve wound healing

Some skin wounds, such as diabetic ulcers, are chronic and may never heal; others, such as burn wounds, are often large and difficult to treat, resulting in pain, infection and scarring. Researchers at the University of California, Los Angeles, funded by the National Institutes of Health, have developed a synthetic biomaterial that fills wounds and aids in regeneration of skin cells, which ultimately improves wound healing.

18 Dec 2015

UB study traces how enigmatic molecules help cancer self-destruct

You've probably never heard of "sphingolipids" before. But these curiously named organic compounds play a vital role in one of humanity's most well-known diseases: cancer.

18 Dec 2015

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited, its drug R&D subsidiary, has initiated SANET-ep, a Phase III sulfatinib (HMPL-012) registration trial in China in patients with extra-pancreatic neuroendocrine tumors ("NETs"), which are all non-pancreatic NETs, including, for example, NETs originating in the lymph, lung and across the gastrointestinal tract.

18 Dec 2015

AGA issues six new clinical practice guidelines

In 2015, the American Gastroenterological Association issued six clinical practice guidelines, all published in AGA's official journal Gastroenterology, offering current, evidence-based point-of-care recommendations to guide physicians at the bedside.

17 Dec 2015

Berkeley Lab researchers develop new mouse model for most common form of breast cancer

The first clinically-relevant mouse model of human breast cancer to successfully express functional estrogen receptor positive (ER+) adenocarcinomas has been developed by researchers at Lawrence Berkeley National Laboratory.

17 Dec 2015

Study offers new view of how cancer cells transform normal cells through 'metastatic hijacking'

Metastasis - or the spread of cancer from one part of the body to other parts - accounts for more than 90 percent of cancer-related deaths. Although the cells that seed metastasis and the sites that they tend to travel to have been increasingly studied over the years, little has been known about how cancer migrates from a primary site, such as breast tissue, to a secondary site, such as the brain or bone marrow.

16 Dec 2015

Study paves way for development of novel cancer therapeutics

A team of scientists, comprising researchers from the Institute of Molecular and Cell Biology, a research institute under the Agency for Science, Technology and Research, Singapore, and the VIB Laboratory of Molecular Cancer Biology, has revealed the mechanism by which tumor cells elevate levels of MDM4, a protein that is highly expressed in cancer cells but not in normal adult tissues.

16 Dec 2015

Array BioPharma reports top-line results from binimetinib Phase 3 trial in patients with NRAS-mutant melanoma

Array BioPharma today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study met its primary endpoint of improving progression-free survival (PFS) compared with dacarbazine treatment.

16 Dec 2015

Heloise Anne Pereira named 2016 National Academy of Inventors Fellow

University of Oklahoma Health Sciences Center Professor Heloise Anne Pereira has been named a 2016 National Academy of Inventors Fellow, a high professional distinction awarded to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society.

16 Dec 2015

VCU Massey Cancer Center scientists reveal signaling process that leads to excessive growth of cancer

The gene p53 has been described as the "guardian of the genome" due to its prominent role in preventing genetic mutations. More than half of all cancers are thought to originate from p53 mutations or loss of function, and now a recent study by VCU Massey Cancer Center scientist Richard Moran, Ph.D., explains why.

15 Dec 2015

CAP2 gene responsible for cardiac conduction disease in mice

The presence or absence of the CAP2 gene causes sudden cardiac death in mice, according to new research from the Perelman School of Medicine at the University of Pennsylvania. In particular, the absence of the gene interrupts the animal's ability to send electrical signals to the heart to tell it to contract, a condition called cardiac conduction disease.

15 Dec 2015

Therapeutics News and Research

New study examines single 'transformer' proteins involved in cancer

Scientists identify 52 genetic variations associated with age-related macular degeneration

Small airway-on-a-chip enables analysis of human COPD and asthma

Alexza reports interim results from AZ-002 Phase 2a study in epilepsy patients

Nuvo Research announces topline results from WF10 Phase 2 trial for treatment of allergic rhinitis

Halozyme Therapeutics, Lilly sign global collaboration and license agreement

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

Regulus begins RG-125(AZD4076) Phase I study for treatment of NASH in patients with type 2 diabetes/pre-diabetes

Adaptimmune begins Phase I/II study of affinity enhanced T-cell therapy targeting MAGE-A10 in NSCLC patients

Synthetic biomaterial aids in regeneration of skin cells to improve wound healing

UB study traces how enigmatic molecules help cancer self-destruct

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

AGA issues six new clinical practice guidelines

Berkeley Lab researchers develop new mouse model for most common form of breast cancer

Study offers new view of how cancer cells transform normal cells through 'metastatic hijacking'

Study paves way for development of novel cancer therapeutics

Array BioPharma reports top-line results from binimetinib Phase 3 trial in patients with NRAS-mutant melanoma

Heloise Anne Pereira named 2016 National Academy of Inventors Fellow

VCU Massey Cancer Center scientists reveal signaling process that leads to excessive growth of cancer

CAP2 gene responsible for cardiac conduction disease in mice

Understanding the DNA Damage Response in Innate Immunity eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News